佰泽医疗(02609)再暴涨超50%，高见17.06港元创上市新高，近两个交易日股价累涨1.3倍。截至发稿， 涨58.01%，报16.19港元，成交额14.37亿港元，总市值突破200亿港元。 消息面上，上交所、深交所近日发布公告，佰泽医疗被调入港股通标的名单，自9月8日起生效。最新数 据显示，佰泽医疗港股通持股占比达0.21%。公开资料显示，佰泽医疗为"肿瘤全周期医疗服务"领域的 服务供应商，在肿瘤全周期医疗服务体系中提供筛查、诊断、治疗、康复等服务。在战略布局方面，佰 泽医疗已在北京、天津、安徽、山西、河南五省市成功运营八家医院。今年上半年，佰泽医疗实现收入 5.75亿元(人民币，下同)，同比增加0.66%；股东应占亏损2762万元，同比扩大139.18%。 ...

Core Viewpoint - Bayzed Health Group successfully listed on the Hong Kong Stock Exchange on June 23, with a strong market debut, reflecting investor confidence in the high-growth cancer medical service sector in China [1] Company Overview - Bayzed Health Group's IPO price was HKD 4.22, with 133 million shares issued, raising approximately HKD 562 million [1] - The cornerstone investor, Harvest Oriental, subscribed for HKD 149 million, accounting for 26.5% of total fundraising and 2.7% of the post-issue equity [1] - The company is positioned as a leader in China's full-cycle cancer medical services, marking a significant milestone in the private specialty medical service sector [1][4] Market Potential - The cancer medical service market in China grew from RMB 337.1 billion in 2018 to RMB 495.1 billion in 2022, with a CAGR of 10.1% [2] - The private cancer medical service market is expected to grow at a CAGR of 19.8% from 2022 to 2026, potentially exceeding RMB 109.2 billion by 2026 [2] - The early cancer screening market presents significant potential, with over 500 million people in China aged 45-74 eligible for screening, indicating a substantial supply-demand gap [2] Business Strategy - Bayzed Health has established a comprehensive service system covering "screening-diagnosis-treatment-rehabilitation," addressing the shortcomings of public healthcare systems [3] - By the end of 2024, the company plans to complete the infrastructure for early cancer screening across all its hospitals [3] - The proportion of revenue from cancer-related services is projected to increase from 39.3% in 2022 to 49.4% in 2024, demonstrating significant commercial success [3] Competitive Position - Bayzed Health ranks third among private cancer medical groups in China based on cancer screening revenue and fourth based on tumor service revenue from its own hospitals [4] - The company leads in the number of early cancer screening centers and gastrointestinal examination cases among private cancer medical groups in China [4] Financial Performance - The company has shown strong growth, with revenue increasing from RMB 803 million in 2022 to RMB 1.189 billion in 2024, reflecting a CAGR of 21.7% [7] - Gross profit rose from RMB 79.56 million to RMB 208 million during the same period, with a CAGR of 61.8%, indicating improved cost control and operational efficiency [7] - In 2024, the company achieved an adjusted net profit of RMB 12.5 million, marking a turnaround from previous losses [8] Future Outlook - The successful IPO and positive financial indicators suggest a robust growth trajectory for Bayzed Health, with expectations of double-digit revenue and profit growth in the coming years [9] - The company plans to utilize IPO proceeds for strategic acquisitions, hospital management, and digital upgrades to enhance business expansion and operational efficiency [9]